tradingkey.logo
tradingkey.logo

New England Journal Of Medicine Publishes Positive Phase 3 Valor Trial Results Of Brepocitinib In Dermatomyositis

ReutersMar 28, 2026 7:26 PM

- Roivant Sciences Ltd ROIV.O:

  • NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES POSITIVE PHASE 3 VALOR TRIAL RESULTS OF BREPOCITINIB IN DERMATOMYOSITIS

  • ROIVANT SCIENCES LTD - FDA GRANTS PRIORITY REVIEW TO BREPOCITINIB NDA WITH PDUFA DATE IN Q3 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI